Abridge, an AI documentation firm for healthcare, is partnering with Eli Lilly and Nvidia to expand beyond physician note-taking into claims processing and clinical trial matching.

What happened

Abridge announced partnerships with drugmaker Eli Lilly (which made a strategic investment in the company) and technology firm Nvidia to build a foundation model for clinical conversations. The company also partnered with the American Diabetes Association, American Academy of Family Physicians, Neurology journal, and Journal of Clinical Oncology to expand clinical decision support, and is collaborating with the American Health Information Management Association on real-time claims processing standards.

Why it matters

AI documentation has become a major use case in healthcare because providers have long worried that administrative paperwork distracts from patient care and extends into after-work hours. However, the AI scribe market is highly competitive—electronic health record vendors like Epic and Oracle Health have entered the space, and their systems are already embedded deeply in clinician workflows. Abridge's expansion into claims resolution and clinical trial screening could help the company compete beyond pure note-taking by offering value to payers and life science companies, though health plans worry that providers' AI documentation tools could increase healthcare costs.

What to watch

Abridge works with more than 300 health systems across the country, including Kaiser Permanente, Johns Hopkins Medicine, and Yale New Haven Health. Northwestern Medicine also plans to roll out Abridge's tools across its health system. The size of Eli Lilly's investment was not disclosed.